Bipolar depression. Bipolar disorder, current episode depressed, mild or moderate severity
Conditions
Interventions
Intervention 1: Intervention group: They receive one capsule in the first week, two capsules daily from the second to the fifth week, and one amantadine capsule in the sixth week. Intervention 2: Cont
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 to 65 years Patients referred to the psychology clinic of Taleghani Hospital. Patients who are diagnosed with bipolar depressive disorder by a doctor based on diagnostic criteria Patients who consent to participate in the study and complete the consent form Patients who are able to take oral medications and are likely to complete assessments. Patients without active ulcers in the gastrointestinal tract.
Exclusion criteria
Exclusion criteria: Patients who are in mania phase Alcohol or drug use Renal impairment (creatinine clearance less than 50 ml/minute) Liver disorders (cirrhotic patients) Having epilepsy or a history of seizures History of eczema Patients with heart failure or arrhythmia Patients with glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression score on the Hamilton Questionnaire. Timepoint: At the beginning of the study and 6 weeks after taking amantadine. Method of measurement: Hamilton Depression Questionnaire.;WHO Quality of Life Questionnaire score. Timepoint: At the beginning of the study and 6 weeks after taking amantadine. Method of measurement: WHO Quality of Life Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Studying the incidence of disease phase change from depression to mania. Timepoint: At the beginning of treatment and 6 weeks after receiving amantadine. Method of measurement: Patient visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaria Tavakoli Ardakani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed